Cluster Headache Syndrome Market Overview
Cluster Headache Syndrome Market Size is estimated to reach $512.3 million by 2027 and is poised to grow at a CAGR of 6.1% over the forecast period of 2022-2027. Cluster headaches are attacks of pain on one side of the head, often felt around the eyes. A cluster headache usually wakes up the person in the middle of the night with intense pain in or around one of the eyes on one side of the head. Cluster periods, which last from weeks to months, are usually followed by remission periods in which the headaches stop. According to NCBI, Cluster headaches are the most common type of trigeminal autonomic cephalgia headache. As they affect only 0.1% of the population, studying the disease process is difficult at best. They are considered one of, if not the, most severe types of headaches and recognition and treatment are critical despite their rarity. Each year, it affects approximately 0.05% to 0.1% of the US population. The growing prevalence of Cluster headaches boosts the growth of the Cluster Headache Syndrome Market in the U.S.
Cluster Headache Syndrome Market Report Coverage
The report: “Cluster Headache Syndrome Market Forecast
(2022-2027)" by IndustryARC, covers an in-depth analysis of the following
segments in the Cluster Headache Syndrome Market.
- Geographically, North America held a dominant market share in the year 2021, owing to the growing rate of cases and increasing demand for treatment driving the Cluster Headache Syndrome Market in the U.S. region.
- The Cluster Headache Syndrome industry is predicted to increase owing to a rise in research and development activities for the treatment in the world.
- The global cluster headache market is hampered by a lack of awareness among healthcare providers and unfavorable healthcare policies that have a negative impact on overall healthcare spending.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Cluster Headache Syndrome Market Report.
Cluster Headache Syndrome Market: Market Share (%) by region, 2021
For More Details On this report - Request For Sample
Cluster Headache Syndrome Market Segment Analysis - by Drugs
Cluster Headache Syndrome Market based
on the drugs can be further segmented into Fast-acting drugs, Long-term drugs
and short-term drugs. The fast-acting drugs segment held a dominant market
share in the year 2021 and is estimated to grow with the fastest CAGR of 7.5%
over the forecast period 2022-2027. This is owing to the quick relief actions
of the drugs. Corticosteroids or anti-inflammatory drugs, such as prednisone,
are fast-acting preventive drugs that can help many people with cluster
headaches, thereby, driving the segment growth.
Cluster Headache Syndrome Market Segment Analysis - by Distribution Channels
Cluster Headache Syndrome Market based
on the application can be further segmented into Hospital Pharmacies, Retail
Pharmacies, Online Stores and Others. The Hospital Pharmacies segment held a dominant market share in
the year 2021. This is owing to the growing number of hospitalizations for
chronic Cluster Headache Syndrome and Episodic
Cluster Headache Syndrome which are largely caused by the growing prevalence of
sedentary lifestyles, which are linked to stressful work environments and long
periods spent on consumer electronic devices.
Online Pharmacies are estimated to grow with the fastest CAGR of 8.3% over the forecast period 2022-2027 owing to the growing demand for online pharmacies in recent years. In May 2021, ASOP Global
Foundation has surveyed 500 American customers, where 42% of Americans were found
to purchase their medications online, there was a 7% increase from the prior
year, primarily owing to the benefits of convenience and perceived lower costs.
Such growing demand for online pharmacies fuels the growth of the Cluster
Headache Syndrome industry over the forecast period 2022-2027.
Cluster Headache Syndrome Market Segment Analysis - by Geography
North America held a dominant market share of 35% in the year 2021. This is mainly driven by the rising number of depression cases in this region. For instance, the National Institute of Mental Health estimates that 21.0 million adult Americans experienced at least one major depressive episode in 2020. This figure corresponded to 8.4% of all American adults. Females had a greater rate of major depressive episodes (10.5%) than males (6.2%) which is likely to boost the Cluster Headache Syndrome Market in the U.S., Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is a result of rising geriatric population levels combined with increased funding for the development of health infrastructure.
Cluster Headache Syndrome Market Drivers
Rising Approval of Drugs to Treat the Cluster Headache is Propelling the Market Growth:
The increasing approval of novel cluster headache treatment options by
regulatory authorities such as the USFDA is propelling the global cluster
headache industry forward. For example, in June 2019 Eli Lilly and Co’s
Emgality injection solution has been approved by the FDA for the treatment of
episodic cluster headaches in adults. The injectable medication is given once
every month for the duration of a cluster phase. Patients suffering cluster
headaches will receive a monthly dose of 300 mg. The medication will cost the
same per milligram as it does for migraines, but the price may change
depending on how long one needed to take it. Emgality for migraines has an
annual cost of $6,900. Such rising approvals are boosting the Cluster Headache
Syndrome industry forward.
The Increasing Incidence of Cluster Headache Patients with a Family History is Boosting the Global Cluster Headache Market.
The rising prevalence of cluster headache patients with a positive
family history is expected to propel the global cluster headache market
forward. For example, as stated in a research article that was published by BMC
(Bio med central) in April 2020, a systematic review and meta-analysis were
carried out in accordance with the guidelines for preferred reporting items for
systematic reviews and meta-analysis protocols (PRISMA- P). The estimated
prevalence of CH patients with a family history was found to be around 6.27%,
with an overall I2 of 73%. Such an increase in chances of Cluster Headache by
family history is boosting the growth of the Cluster Headache Syndrome Industry.
Cluster Headache Syndrome Market Challenge
Lack of Awareness is Poised to Hamper the Market Growth:
Lack of awareness and unfavorable healthcare policies that have a negative impact on total healthcare spending are expected to be the primary factors restraining growth in the cluster headache disease market. Other factors limiting market growth include the lengthy drug approval process and strict regulatory pathways. According to a survey report that was published in NCBI in 2019, in total, 1,161 patients completed the study, 28% of participants knew they had migraines, Sixty-four percent of migraine sufferers referred to their condition as a "headache"; other less prevalent phrases were "cervical pain" (4%), "tension headache" and "sinusitis" (1%). Although headaches and migraines are relatively common diseases, there are still some nations where patients and doctors are not aware of the condition. This is acting as a restraining factor that is hampering the market growth.
Cluster Headache Syndrome Industry Outlook
Product launches, mergers & acquisitions, joint ventures and geographical
expansions are key strategies adopted by players in the Cluster Headache
Syndrome Market. The top 10 companies in the Cluster Headache Syndrome Market
- Zosano Pharma
- Eli Lilly and Company
- Lundbeck Seattle BioPharmaceutical
- Winston Laboratories, GlaxoSmithKline plc.
- ElectroCore Medical LLC
- Autonomic Technologies, Inc.
- AstraZeneca plc., Allergan plc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- In June 2021, the agreement for the global rights to Zomig (zolmitriptan) outside of Japan was announced by AstraZeneca. An area of medicine outside of AstraZeneca's strategic emphasis, the acute treatment of migraines and cluster headaches with Zomig is indicated.
- In May 2021, according to a release from Unity HA, the Pulsante® SPG Microstimulator System has been given Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute pain brought on by persistent cluster headaches.
- In June 2019, Eli Lily and company, an American pharmaceutical company got the food and drug administration approval of Galcanezumab, an antibody that is used for migraines as well as the cluster headache.
Report Code: HCR 0150
Report Code: HCR 93908
Code: HCR 0116
For more Lifesciences and Healthcare Market reports, please click here